Wockhardt shares climb 2% after USFDA makes nil observation

NEW DELHI: Shares of pharmaceutical firm Wockhardt climbed over 2 per cent in early trade on Monday.

Shares of the company got tractions after it said that the USFDA's inspection of its Bioequivalence centre in Aurangabad, Maharashtra yielded no observations.

In a regulatory filing, the company said no observations were made after the US drug regulator inspected its Bioequivalence centre during which Bioequivalence studies of Tamsulosin 0.4mg capsules and Metoprolol Tartrate 200mg ER tablets were audited.


"At the end of inspection, there was nil observation (i.e. zero 483 observation), signifying that best practices were followed, in compliance to applicable regulations. This outcome would lead approvals of ANDAs in pipeline for which Bioequivalence studies are being or will be done in the said Centre," the company said.

Shares of the company closed 0.75 per cent up at Rs 452.60 apiece on BSE.